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Abstract: Although porcine aortic valves or pericardial tissue mounted on a stent have made 
implantation techniques easier, these valves sacrifice orifice area and increase stress at the 
  attachment of the stent, which causes primary tissue failure. Optimizing hemodynamics to prevent 
patient–prosthetic mismatch and improve durability, stentless bioprostheses use was revived in 
the early 1990s. The purpose of this review is to provide a current overview of stentless valves 
in the aortic position. Retrospective and prospective randomized controlled studies showed 
similar operative mortality and morbidity in stented and stentless aortic valve replacement 
(AVR), though stentless AVR required longer cross-clamp and cardiopulmonary bypass time. 
Several cohort studies showed improved survival after stentless AVR, probably due to better 
hemodynamic performance and earlier left ventricular (LV) mass regression compared with 
stented AVR. However, there was a bias of operation age and nonrandomization. A randomized 
trial supported an improved 8-year survival of patients with the Freestyle or Toronto valves 
compared with Carpentier–Edwards porcine valves. On the contrary, another randomized study 
did not show improved clinical outcomes up to 12 years. Freedom from reoperation at 12 years 
in Toronto stentless porcine valves ranged from 69% to 75%, which is much lower than for 
Carpentier–Edwards Perimount valves. Cusp tear with consequent aortic regurgitation was the 
most common cause of structural valve deterioration. Cryolife O’Brien valves also have shorter 
durability compared with stent valves. Actuarial freedom from reoperation was 44% at 10 years. 
Early prosthetic valve failure was also reported in patients who underwent root replacement 
with Shelhigh stentless composite grafts. There was no level I or IIa evidence of more effec-
tive orifice area, mean pressure gradient, LV mass regression, surgical risk, durability, and late 
outcomes in stentless bioprostheses. There is no general recommendation to prefer stentless 
bioprostheses in all patients. For new-generation pericardial stentless valves, follow-up over 
15 years is necessary to compare the excellent results of stented valves such as the Carpentier–
Edwards Perimount and Hancock II valves.
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Introduction
Homografts for aortic valve replacement (AVR) were the first biologic stentless pros-
theses used in clinical practice in the 1960s.1,2 Binet et al3 introduced a stentless porcine 
bioprosthesis, but the valve was abandoned because of poor tissue fixation. Due to 
limited availability and a relatively difficult implantation technique, mechanical AVR 
became the popular therapeutic option. The disadvantage of life-long anticoagulation 
therapy in mechanical AVR prompted the development of xenogeneic bioprostheses. 
Although porcine aortic valves or pericardial tissue mounted on a stent made the Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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implantation technique easier, these valves sacrificed orifice 
area and increased stress at the attachment of the stent, which 
caused earlier primary tissue failure. Optimizing hemody-
namics to prevent patient–prosthetic mismatch and improve 
durability revived the use of stentless bioprostheses in the 
early 1990s. The purpose of this review is to provide a current 
overview of stentless valves in the aortic position.
Various stentless bioprostheses 
and implantation technique
First-generation stentless bioprostheses were the Freestyle 
valve4 (Medtronic, Minneapolis, MN) and the Prima valve5 
(Edwards Lifesciences, Irvine, CA) as well as a porcine 
root and fully scalloped Toronto stentless porcine valve 
(SPV)6 (St Jude Medical, Minneapolis, MN). The O’Brien 
porcine stentless valve7 (CryoLife, Atlanta, GA) and Bio-
cor porcine bioprosthesis (Biocor Industria e Pesquisa, 
Belo Horizonte, MG, Brazil)8 were also introduced to 
the market, but have not found widespread acceptance. 
  Subcoronary and full-root replacements are major implan-
tation techniques. Mini-root replacement, which is an 
inclusion technique, has been preferred to avoid bleeding 
from suture lines at the aortic annulus. The advantage of 
subcoronary implantation is to avoid the manipulation of 
coronary arterial ostia. The disadvantages are difficulties 
occurring in the small aortic annulus and calcified aortic 
root, and possibilities of valve insufficiency by chang-
ing the shape of the stentless valves in a diseased aortic 
root. The full-root technique requires reimplantation of 
coronary arteries to the stentless valves. The advantage of 
this technique is a larger orifice area compared with the 
subcoronary technique, especially in patients with small 
aortic annulus. The full-root technique restores the physi-
ological function of the Valsalva sinus and the sinotubular 
junction, as identified by da Vinci in the 15th century. The 
disadvantage is the difficulty of reoperation when the aortic 
wall of the stentless valve calcifies.
The second generation of stentless valves improved 
the technical difficulties related to free-hand implantation 
with two rows of sutures for subcoronary implantation. The 
Shelhigh Super Stentless aortic porcine valve (Shelhigh, Inc, 
Millburn, NJ)9 is one of the bioprostheses that require only 
one row of sutures. The tip of each commissure is attached 
to the aortic wall. This valve is mounted on a super-flexible 
ring, preserved with glutaraldehyde, detoxified, and heparin 
treated with the No-React anticalcification treatment. This 
valve is easier to implant and possible to use in cases of a 
calcified aortic wall.
The third generation of stentless valves was pericardial 
bioprostheses. A bovine Sorin Pericarbon Freedom10 and an 
equine 3F heart valve11 are available in the market. These 
pericardial valves are flexible, easy to implant, and show an 
extremely good hemodynamic performance.
AVR is the treatment of choice for a vast majority of 
patients. However, in a subset of patients, ie, elderly patients 
with various comorbidities such as chronic renal failure, liver 
cirrhosis, chronic obstructive lung disease, and porcelain 
aorta, AVR is considered contraindicated because of too high 
predicted mortality and morbidity rates. Recent advances in 
valve technology have demonstrated that transcatheter aortic 
valve implantation is feasible and real. Edwards Sapien12 and 
Medtronic CoreValve13 are commercially available for tran-
scatheter aortic valve implantation. The concept of these valves 
is used for new-generation sutureless stentless valves.14,15
Operative outcomes
Reports of the operative mortality of stentless and stented AVR 
have differed in the literature.16 Retrospective and prospective 
randomized controlled studies showed similar operative 
mortality and morbidity. Although stentless AVR required 
longer cross-clamp and cardiopulmonary bypass time, it did not 
impair the postoperative outcomes. In patients with depressed 
LV function, operative outcomes were better in stentless valves 
owing to the larger orifice area when the full-root technique 
was applied to avoid patient–prosthetic mismatch.16
Luciani et al17 reported survival rates after stentless and 
stented xenograft AVR. The stented valve was Hancock II 
bioprosthesis (Medtronic). Stentless bioprostheses were 
mainly the Biocor valve, Toronto SPV valve, and O’Brien 
valve. Hospital mortality was significantly (P , 0.02) higher 
in the stented group (6.2%) than in the stentless group (2.7%). 
Logistic regression analysis showed smaller aortic annulus, 
duration of aortic cross-clamp time, and coronary artery dis-
ease requiring coronary artery bypass as the predictive risk of 
hospital mortality. The stented valve was not a risk factor by 
itself. As a retrospective case match study, Vrandecic et al18 
compared the clinical outcomes of Biocor porcine stented 
valves and stentless valves implanted between 1990 and 1999. 
There was no significant difference in hospital   mortality 
(stented 5.4% and stentless 4.4%, P = 0.79).
Ali et al19 compared the Prima Plus stentless valve with 
the Carpentier–Edwards Perimount valve in a prospective 
randomized fashion. Although there was no significant differ-
ence in the mean aortic annular size, patients in the stentless 
group received a larger valve prosthesis (25.3 mm ± 2.0 mm 
versus 23.2 mm ± 2.0 mm, P , 0.001). Myocardial ischemic Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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time and cardiopulmonary bypass time was about 30 minutes 
longer in the stentless group. Thirty-day mortality (2.5% in 
stented valve and 3.7% in stentless valve) and postopera-
tive morbidity were similar. Chambers et al20 compared the 
Toronto SPV valve with the Carpentier–Edwards Perimount 
valve in a prospective randomized fashion. The average 
labeled size of both valves was 24.7 mm. Thirty-day mortality 
was 3.5% with the stented valve and 4.0% with the stentless 
valve, and postoperative morbidity was similar. Dunning 
et al21 also compared the second-generation stentless valve 
Sorin Freedom with the Sorin More stented valve in a pro-
spective randomized controlled trial. Patients in the stentless 
group received a larger valve prosthesis (25.7 mm ± 2.7 mm) 
than those in the stented group (22.9 mm ± 2.5 mm) 
(P , 0.001). The bypass time and cross-clamp time were 
about 10 minutes longer in the stentless group. Thirty-day 
mortality was 3.2% with the stented valve and 0% with the 
stentless valve, and postoperative morbidity was similar.
Long-term outcomes
Long-term outcomes of various stentless bioprostheses 
have been reported (Table 1).22–30 Several studies showed 
an improved survival after stentless AVR, probably due 
to better hemodynamic performance and earlier LV mass 
regression compared with stented AVR.31–38 However, there 
was a bias of operation age and nonrandomization. A ran-
domized trial supported improved survival of patients with 
stentless valves. Lehman et al39 compared the Freestyle or 
Toronto valves with Carpentier–Edwards porcine valves. 
Eight-year survival was significantly (P = 0.04) better in 
the stentless group (78.1% ± 3.8%) than in the stented group 
(66.0% ± 4.9%). On the contrary, another randomized study 
did not show improved clinical outcomes for up to 12 years. 
Cohen et al40 compared the Toronto SPV valve with the 
Carpentier–Edwards Perimount valve. Freedom from valve-
related morbidity at 12 years was 82% ± 7% in the stented 
group and 55% ± 7% in the stentless group (P = 0.05). The 
actuarial survival rate at 12 years was 35% ± 7% in the 
stented group and 52% ± 7% in the stentless group (P = 0.37). 
Although improved hemodynamic outcomes were obtained 
in patients with a Toronto SPV valve, clinical outcomes were 
similar in both groups.
The long-term results over more than 10 years were 
excellent with the Freestyle valves.23 However, the degenera-
tion was still present in the Toronto SPV valves more than 
10 years after implantation.24 Regarding structural valve dete-
rioration and survival benefit, longer follow-up is necessary 
to compare the excellent results of stented valves such as the 
Carpentier–Edwards Perimount and Hancock II valves.
Hemodynamic advantages
LV hypertrophy and increased LV mass were highly 
  correlated with sudden death, congestive heart failure, stroke, 
myocardial infarction, coronary artery disease, and other 
cardiovascular events.41 Incomplete regression of LV mass 
and LV function after AVR was also related to poor long-term 
survival.42 Therefore, pressure gradient across the implanted 
valve is one of the most important issues in AVR.
Early postoperative hemodynamic performance was 
not different between stentless and stented valves, though 
implanted valve size was larger in stented AVR.43–46 The 
hemodynamic advantage of stentless AVR is not unanimous, 
though stentless valves one size larger could be implanted if 
the aortic annulus has the same size. Subcoronary implanta-
tion of stentless prostheses does not necessarily allow for 
larger valve selection compared with stented valves, because 
the LV outflow suture line is within the aortic annulus. The 
stented valves can be placed in a supra-annular position, 
upsizing from the true aortic annular size. New-generation 
Carpentier–Edwards Perimount Magna (Edwards Life-
sciences, Irvine, CA) valves had a better hemodynamic 
performance compared with stentless Edwards Prima Plus 
(Edwards Lifesciences) valves regarding pressure gradient 
and effective orifice area.47 No difference was found when the 
Prima Plus valve was compared with the Perimount pericar-
dial valve.37,48,49 Compared with porcine stented valves, hemo-
dynamic performance was better with   stentless valves.39,50,51 
A faster and better recovery of LV function and mass 
Table 1 Comparison of stented and stentless valves
Criteria Result
Operative mortality Similar
early outcomes Similar (cohort and RCT study)
Late outcomes Stentless group better (Cohort study)
Similar or slightly better in stentless  
group (RCT study)
Hemodynamics
  Mean PG and eOA Stentless better than porcine valve
Similar to pericardial valve
Stented C–e Magna valve better than  
stentless Freestyle valve
  LV mass regression
  ,6 months Better in stentless group (most cohort 
and RCT study)
  .12 months Similar (cohort and RCT study)
Durability and SVD Better in stented groupa
Note: aCompared with the first-generation stentless valves.
Abbreviations: C–E, Carpentier–Edwards; EOA, effective orifice area; LV, left 
ventricular; PG, pressure gradient; RCT, randomized controlled trial; SVD, structural 
valve deterioration.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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has been reported after stentless AVR.36,52–57 Implantation 
technique was also related to the improved hemodynamics. 
A full-root technique can implant a larger stentless valve 
in the supra-annular position, allowing upsizing, compared 
with the original aortic annulus.58,59 There may be a bias 
in the selection of stentless or stented valves by surgeons, 
because more complicated aortic root anatomy leads to the 
more frequent selection of stented valves in the learning 
curve period.
In randomized studies, better hemodynamic results 
were obtained with Freestyle,57,60 Sorin Freedom,21 Prima 
Plus,48,61,62 and Toronto SPV valves20,43 compared with stented 
valves. Although Freestyle valves showed a greater reduction 
in peak velocity and a greater increased effective orifice area 
than Mosaic porcine valves, there was a similar reduction 
in LV mass index and clinical outcomes at 6 months and 
12 months after the operation.57 Narang et al60 compared the 
Freestyle valves with Carpentier–Edwards Perimount valves. 
LV ejection fraction, LV mass, New York Heart Associa-
tion scale, and mean pressure gradient were similar in both 
groups. However, in patients with LV ejection fraction less 
than 50% and implanted valve less than 19 mm, there was a 
significant difference in LV mass index and mean pressure 
gradient. Sorin Freedom stentless valves had a better pressure 
gradient and effective orifice area than Sorin More stented 
valves.21 However, there was no significant difference in LV 
mass index at 12 months after the operation. Ali et al48 com-
pared Prima Plus valves with Carpentier–Edwards Perimount 
valves. There was no difference in mean pressure gradient 
and LV mass 8 weeks postoperatively. Similar results were 
obtained by Doss et al61 and Risteski et al62 in patients over the 
age of 75 years. Chambers et al20 and Cohen et al43 compared 
Toronto SPV valves and Carpentier–Edwards Perimount 
valves in a randomized fashion. The effective orifice area, 
mean pressure gradient, and LV mass index were similar 
12 months after the operation.
Stentless valves showed no pressure gradient during 
dobutamine stress echocardiography in comparison with 
elevated transvalvular gradient in mechanical valves.45 
Several studies demonstrated superior hemodynamics under 
exercise with stentless valves compared with mechanical 
valves after AVR.63,64 Fries et al44 compared 23 mm Freestyle 
valves implanted by the full-root technique with native aor-
tic valves and 23 mm Carpentier–Edwards Perimount valves. 
There was a significant increase of pressure gradient in the 
stented valve group under exercise, though the native valve 
group and the stentless valve group showed no increase in 
pressure gradient under exercise.
An improved hemodynamic performance resulted in 
faster LV mass reduction in patients with aortic stenosis and 
LV hypertrophy.65 A meta-analysis showed a faster LV mass 
reduction in patients with stentless AVR than in those with 
stented AVR.52 However, some studies showed no differences 
in LV mass reduction.57,60–62 Although faster LV mass regres-
sion has been reported after stentless AVR, it was obtained 
by larger valve implantation, and final LV mass regression 
was not significant 1 year after AVR.21
Degeneration and durability
Primary tissue failure is an important issue after biological 
valve implantation (Table 2). Theoretically, xenogenic stent-
less aortic valves have better durability by avoiding stress at 
the stent sites.66 The hypothesis that durability is improved 
by avoiding tissue stress as far as the treatment method is 
the same as the stented counterparts cannot be proved yet. 
The freedom rate from structural valve deterioration of the 
Freestyle valves was 97% at 10 years after AVR,23 which was 
similar to stented AVR.67 A major cause of structural valve 
deterioration was cusp tear.68 Toronto SPV valve demonstrated 
significant degeneration and an increase in LV mass at 10-year 
follow-up after AVR.40 Freedom from reoperation at 12 years 
was 75%, which is much lower than with the Carpentier–
Edwards Perimount valve (92%). Cusp tear with consequent 
aortic regurgitation was the most common cause of structural 
valve deterioration. Urgent or emergent reoperation was 
necessary due to hemolytic anemia and congestive heart 
failure. The Toronto valve group also reported that 12-year 
freedom from reoperation AVR was as low as 69%.24 The 
Carpentier–Edwards Perimount valve deteriorated with 
sclerosis and calcification rather than cusp tear by pathological 
study,69 which could permit the elective reoperation in patients 
of stable condition. The first-generation Cryolife O’Brien 
valve also has shorter durability compared with stent valves. 
Actuarial freedom from reoperation was 94% at 5 years and 
44% at 10 years.70 Early prosthetic valve failure was also 
reported in patients who underwent root replacement with 
the Shelhigh stentless valve and composite graft.71
The information of durability of xenogenic stentless 
valves in younger patients is absent because the majority of 
these valves are replaced in patients older than 50 years. Only 
Vrandecic et al18 reported the better durability of Biocor stent-
less bioprostheses than of its counterparts in patients with a 
mean age of 48.1 years and 46.1 years. Although   long-term 
results of homograft aortic valves are excellent, faster 
  calcification in homografts has been reported compared with 
Freestyle stentless valves in a younger age group.72Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Recommended indication 
of stentless valves
Homografts have been believed to be the substitute of choice 
in patients with active infective endocarditis. However, there 
was no difference in susceptibility to infection between 
homografts and mechanical valves.73 Several reports of cures 
for infective endocarditis with stentless valves have been 
demonstrated as the substitute of the homograft,74–76 which 
is not easily available in many countries.
Stentless bioprostheses were thought to replace stented 
biological valves by better hemodynamic performance and 
longer durability when they were introduced in the early 
1990s. In 2008, less than 12% of all aortic valve prostheses 
implanted in Europe were stentless.49 The low percentage of 
stentless valves was attributed to similar hemodynamic per-
formance and easier implanting technique of new-generation 
bioprostheses such as Carpentier–Edwards Perimount Magna 
valve and Medtronic Mosaic Ultra valve. The durability of 
long-term outcomes was not better than expected. A demand-
ing, cumbersome technique prolongs cardiac ischemic and 
bypass time and increases risk to the patient. Most surgeons 
now tend to implant stented valves in complicated cases and 
octogenarians, knowing that operative mortality and durabil-
ity are not worse than with stentless AVR. Stentless valves 
with an easier implantation technique (one suture line or 
sutureless) may increase the market of stentless bioprostheses 
in the future.
There was no level I or IIa evidence of better   hemodynamic 
performance, LV mass regression, surgical risk, durability, 
and late outcomes. At present, stentless bioprostheses are 
recommended in relatively young and active patients with 
impaired LV function and small aortic annulus. There is no 
general recommendation to prefer stentless bioprostheses 
in all patients.
Bioprostheses for transcatheter aortic valve implantation 
does not have long-term outcomes.12,13 Following the previ-
ous literature on stentless valves, modification of stentless 
bioprostheses used in the transcatheter technique should be 
restricted to patients with serious comorbidity or octogenar-
ians contraindicated to standard AVR. Autologous pericardial 
stentless valves should also be limited to younger age groups 
of patients aged less than 50 years.77
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